Source:http://linkedlifedata.com/resource/pubmed/id/10516698
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1999-12-27
|
| pubmed:abstractText |
From August 1987 to March 1995, 25 patients with high-grade B cell non-Hodgkin's lymphoma (NHL) were treated with high-dose therapy (HDT) followed by bone marrow purged with immunomagnetic beads. At the time of transplantation, 20 patients were in sensitive relapse and five in first complete or partial remission. Ten patients had secondary high-grade NHL transformed from low-grade NHL. The HDT consisted of TBI followed by high-dose cyclophosphamide. All patients engrafted, except for two patients with early treatment-related death. Eleven patients relapsed, of whom nine died of lymphoma, and two are alive in new CR. The estimated event-free and overall survivals at 5 years were 40% and 48%, respectively, with a median follow-up of 48 months (range 1-123). Eight of the tumours contained the translocation t(14;18) at the major breakpoint region (MBR) of BCL-2. In these patients the presence of tumour cells in the bone marrow graft before and after purging were assessed by PCR. Four of five patients infused with non-detectable minimal residual disease in their autografts are in complete remission, while two of three patients reinfused with t(14;18) positive cells after purging, experienced a fast and aggressive relapse. As found by others, our data suggest that reinfusion of tumour-free autografts obtained by efficient in vivo purging using chemotherapy before harvesting, and/or by in vitropurging of the stem cell products, influence the patients remission status after HDT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
865-72
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10516698-Adolescent,
pubmed-meshheading:10516698-Adult,
pubmed-meshheading:10516698-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10516698-Bone Marrow Purging,
pubmed-meshheading:10516698-Bone Marrow Transplantation,
pubmed-meshheading:10516698-Chromosomes, Human, Pair 14,
pubmed-meshheading:10516698-Chromosomes, Human, Pair 18,
pubmed-meshheading:10516698-Combined Modality Therapy,
pubmed-meshheading:10516698-Female,
pubmed-meshheading:10516698-Graft Survival,
pubmed-meshheading:10516698-Humans,
pubmed-meshheading:10516698-Immunomagnetic Separation,
pubmed-meshheading:10516698-Lymphoma, B-Cell,
pubmed-meshheading:10516698-Male,
pubmed-meshheading:10516698-Middle Aged,
pubmed-meshheading:10516698-Survival Analysis,
pubmed-meshheading:10516698-Translocation, Genetic,
pubmed-meshheading:10516698-Transplantation, Autologous
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo, Norway.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|